180 related articles for article (PubMed ID: 15886501)
1. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
3. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Lundin M; Kokkola A; von Boguslawski K; Haglund C
Int J Cancer; 2001 Jan; 95(1):1-6. PubMed ID: 11241302
[TBL] [Abstract][Full Text] [Related]
4. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
Lundin M; Nordling S; Lundin J; Isola J; Wiksten JP; Haglund C
Oncology; 2005; 68(4-6):306-13. PubMed ID: 16020957
[TBL] [Abstract][Full Text] [Related]
5. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
7. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma.
Hrabar D; Aralica G; Gomercic M; Ljubicic N; Kruslin B; Tomas D
Anticancer Res; 2010 Jul; 30(7):2749-53. PubMed ID: 20683009
[TBL] [Abstract][Full Text] [Related]
8. A prognostic value of syndecan-1 in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers.
Conejo JR; Kleeff J; Koliopanos A; Matsuda K; Zhu ZW; Goecke H; Bicheng N; Zimmermann A; Korc M; Friess H; Büchler MW
Int J Cancer; 2000 Oct; 88(1):12-20. PubMed ID: 10962434
[TBL] [Abstract][Full Text] [Related]
10. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
11. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
12. [Is syndecan-1 an independent prognostic factor in patients with laryngeal carcinoma?].
Klatka J; Skomra D; Paduch R; Kupisz K; Tryka E; Harytanowicz M; Kłos A
Otolaryngol Pol; 2004; 58(5):933-40. PubMed ID: 15732779
[TBL] [Abstract][Full Text] [Related]
13. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
14. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
[TBL] [Abstract][Full Text] [Related]
15. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer.
Juuti A; Lundin J; Nordling S; Louhimo J; Haglund C
Oncology; 2006; 71(1-2):61-8. PubMed ID: 17377415
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
[TBL] [Abstract][Full Text] [Related]
18. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
20. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
Ro Y; Muramatsu T; Shima K; Yajima Y; Shibahara T; Noma H; Shimono M
Int J Oral Maxillofac Surg; 2006 Mar; 35(3):252-7. PubMed ID: 16280239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
